INTRODUCTION
Rabies virus causes a fatal disease associated with intense viral replication in the central nervous system. The infectious agent is a lyssavirus which belongs to the rhabdovirus family. Its negative strand RNA genome is sequentially transcribed into one leader RNA at the 3' end (Kurilla et al., 1984) and five monocistronic mRNAs (Coslett et al., 1980; encoding successively the N, M1, M2, G and L proteins (Flamand & Delagneau, 1978; Tordo et al., 1986) .
The rabies virion is composed of a transcriptionally active nucleocapsid (Kawai, 1977; Flamand et al., 1978) containing the RNA molecule (about 12 000 nucleotides long) wrapped in three protein species: the nucleoprotein N, the phosphoprotein M 1 and the RNA polymerase L; this nucleocapsid is surrounded by a lipid bilayer associated with M2 and a transmembrane glycoprotein G. In addition to the five viral proteins, some contaminants of cellular origin such as actin are included in the virion (Naito & Matsumoto, 1978) .
In order to investigate the various steps of the viral cycle as well as the molecular basis of rabies pathogenesis, antigenic and temperature-sensitive (is) mutants have been isolated in different laboratories. We have previously demonstrated that specific antigenic mutations lead to a reduced virulence for adult animals (Coulon et al., 1982 (Coulon et al., , 1983 Pr6haud et al., 1988) . The mutations have been localized by direct sequencing of the RNA genome and they affect antigenic site II or III of the glycoprotein (Dietzschold et al., 1983; Self et al., 1985; Pr6haud et al., 1988) .
In order to study the involvement of each viral protein in the viral cycle, a collection of 76 ts mutants has been isolated in our laboratory. The mutants were separated into three groups according to their ability to synthesize viral proteins at the non-permissive temperature (NPT) (Saghi & Flamand, 1979) : (i) F-, no viral proteins could be detected in infected cells at the NPT; (ii) F +/-, viral protein synthesis at the NPT was low but detectable, 80~ of the mutants belong to this group; (iii) F +, the transcription, replication and protein synthesis capabilities were comparable to that of the wild-type. Only three F + mutants have been described. Unfortunately, mutants of various phenotypes, which were probably affected in different viral proteins, failed to complement each other (Bussereau et al., 1982b) , making assignments of the mutations to the viral genes difficult. Nevertheless the ts lesion of two F +/-mutants, tsO106 and tsO52, C. PRt/HAUD AND OTHERS could be localized in M1 because it resulted in an altered migration of this protein in SDSpolyacrylamide gels (Saghi et aL, 1981) . In both cases, at least one temperature-resistant revertant regained a normal migration pattern.
Studies on the pathogenicity of the mutants for adult mice when administered via the intramuscular route were also deceptive: many intermediates between unaltered pathogenicity and partial attenuation were found. Animals surviving inoculation with the ts mutants were challenged with the GS strain. Results indicated that the less pathogenic mutants were less protective, and this observation further suggested that the attenuation was only due to a block in viral multiplication at the body temperature of the animal (Aubert et al., 1980; Bussereau et al., 1983) . In view of these results, the study of this first series of ts mutants was abandoned.
We have now isolated and characterized an F + ts mutant, tsG1, which has new characteristics: it is avirulent and protects animals against challenge by pathogenic viruses, and at the NPT it has no c.p.e, in cell culture and establishes immediate persistent infection,
The ts lesion has been localized in the G gene. The transport of the G protein t ° the external membrane has been investigated. Results indicate that tsG1 has a unique phenotype among ts mutants affecting a transmembrane protein of an enveloped virus.
METHODS

Cells and virus.
The BSR clone of BHK-21 (baby hamster kidney) cells and CER hamster cells were grown in Eagle's MEM supplemented with 10~ calf serum.
The CVS (Challenge Virus Standard) strain of rabies virus was obtained from P. Atanasiu (Institut Pasteur, Paris, France). tsG 1 was derived from a plaque-purified CVS subclone. Titres were determined by plaque assay on CER cell monolayers as previously described (Bussereau et aL, 1982a) . Our viral stocks did not contain a significant amount of defective interfering particles.
One-step growth curves. Confluent BSR monolayers (3 x 106 cells) were infected with 0.2 ml of the viral suspension at an m.o.i, of l0 p.f.u./cell. Adsorption was for 45 min at room temperature. Cells were then washed twice and incubated at 33, 37, 38.5 or 39.6 °C in 3 ml of MEM supplemented with 2~ calf serum in a 5~ CO2 atmosphere. The medium was changed after l h to remove desorbed virus. Aliquots (0.2 ml) were taken at various periods of time and titrated at 33 °C on CER monolayers.
Determination ofviralprotein synthesis. BSR monolayers were infected as above and incubated for 18 h at 33 or 39.6 °C in 3 ml of 2 ~ calf serum in MEM in a 5 ~ CO2 atmosphere. The growth medium was then removed and replaced by 3 ml of methionine-deprived MEM supplemented with 13 ~tCi of [35S]methionine (800 Ci/mmol; CEA, Saclay, France). Cells were incubated for an additional 2 h at 33 or 39.6 °C in a 5~ CO2 incubator. Cell extracts were then prepared as previously described by Saghi & Flamand (1979) and analysed on slab gels following the Laemmli (1970) procedure. Gels were fixed in methanol-acetic acid-water (3 : 1 : 6, v/v/v), treated for fluorography, dried and exposed to Kodak X-Omat at -70 °C as described by Bonner & Laskey (1974) .
HPLC tryptic peptide mapping method. The preparation of tryptic peptides labelled with [3H]-or [14C]lysine has been described by Lafay & B~n~jean (1981) and Diallo (1984) . Peptides were resolved by HPLC on a Beckman ultrasphere octadecylsialyl column. HPLC conditions were as follows. Solvent A was 8.3 mM-H3POa pH 2.3 and solvent B was a mixture of 30% 8-3mM-H3PO,, pH2.3 and 70% CH3CN. A gradient of 0 to 100% solvent B was run for 60 min at a flow rate of 1 ml/mm at room temperature.
Nucleotide sequence analysis. The sequencing procedure was according to Seif et al. (1985) , and the dideoxy chain termination method of Sanger et al. (1977) was used. Reverse transcription was performed directly on the genomic RNA using synthetic oligonucleotides to prime the reaction. The first reaction was primed with a mixture of eight primers of the following sequence: 5'-ATGGTXCCTCAAGTT-3 '. The four other primers had the following sequences: 5'-AGAGGCAGAGACCTA-3', 5'-GATTACACCATTTGGAT-3', 5"-GTCCCAGGGTTTG-GAAA-3' and 5'-GCACCCCCTGGCTGA-3". They were all synthesized at the Pasteur Institute except the third, which was generously donated by D. H. L. Bishop, Oxford, U.K.
Immunofluorescence tests. Sterile chambers (Lab-Tek, Miles Laboratories) containing 105 BSR cells were infected with the virus at an m.o.i, of 100 p.f.u./cell and incubated for 24 h at 33 or 39.6 °C. Fluorescent antinucleocapsid antibodies (Pasteur Institute) were used for the detection of the N protein. A mixture of three antiglycoprotein monoclonal antibodies (MAbs) from our collection (24B6, 11 C6, 25A 1) and fluorescent anti-mouse immunoglobulins (Cappel Laboratories) were used for indirect detection of the G protein. Detection of viral proteins was performed after permeabilization of the cells with formalin or on living cells, For the former, cells were washed twice with TD (0.8 mM-Tris-HC1 pH 7.4, 150 mM-NaCI, 5 mM-KC1, 0.7 mM-Na2HPO4), permeabilized with 3.7~ paraformaldehyde in water for 20 min at 33 or 39.6 °C, washed twice with 0-2 Mphosphate buffer pH 7.2 and incubated with anti-nucleocapsid antibodies (Pasteur Institute) for 1.5 h at 37 °C. The preparations were washed twice with phosphate buffer and once with water; they were observed under u.v.
light. For detection in living cells, after washing with TD, the cells were incubated for 1-5 h at 33 or 39-6 °C with pre-warmed antibodies diluted in MEM. Ceils were then washed twice with pre-warmed TD, fixed with 3-7~ paraformaldehyde for 20 min at 33 or 39.6 °C, washed twice with phosphate buffer and incubated with fluorescent anti-mouse immunoglobulins at 37 °C for 1.5 h. Until the fixation step, cells and media were strictly maintained at either 33 or 39.6 °C. Ceils were then washed twice with phosphate buffer and once with water; they were observed under u.v. light.
Pathogenic and protective power of the mutants. Five 6-week-old OF1 female mice (Iffa Credo) were inoculated in the masseter muscle with 50 ~tl of serial 10-fold dilutions of the virus. The exact dose injected was measured by plaque assay on CER cells. The number of mice surviving at each dilution was recorded for 14 days, at which time the dose effect curve was established. The LDs0 was calculated by the K~irber method (K/irber, 1931) . One week later the surviving mice were challenged with 106 p.f.u, of CVS by the same route.
RESULTS
Isolation and preliminary characterization of tsG1
tsG 1 was isolated from a clone of the CVS strain of rabies virus. It did not form plaques at 38.5 °C although the titre at 33 °C was normal. The production of p.f.u, by BSR-infected cells at different temperatures has been studied ( Fig. 1 ). At 33 °C and 37 °C the maturation of p.f.u was normal. In contrast, at 38.5 °C it was only 10~, and at 39.6 °C it was less than 1 ~o of that of the wild-type CVS. In order to verify that cells were not producing unstable viruses, the viral production during a short period (1 h) at the peak of maturation was measured. The 1 h production at 39.6 °C was roughly equal to 1 ~o of that observed at 33 °C. A similar figure was obtained with the 24 h productions (Table 1) , which argues against thermal inactivation of the virus during incubation at high temperature. Whatever the temperature, the 1 h production was equal to 10~ of the cumulative production.
Pathogenic and protective power of tsG1 for adult mice
The pathogenic power of tsG 1 was investigated. Serial dilutions of the virus were inoculated into a series of five adult mice and the survival of animals was subsequently checked during the following 14 days (Fig. 2 ). tsGl exhibited a pathogenicity similar to that of CVS administered via the intracerebral (i.c.) route (an LDso of 50 and 20 p.f.u./inoculum respectively), and a complete avirulence after intramuscular (i.m.) inoculation (for CVS, an LD50 of 250 p.f.u./inoculum by this route). Surviving animals were challenged intramuscularly with 106 p.f.u. (103.6 LD 5°) of CVS. A high level of protection was obtained with at least 103.5 p.f.u, of tsG1 per animal (Tidke et al., 1987) . . Experiments were performed according to Saghi & Flamand (1979) . Titrations were done in CER cells at 33 °C. Bussereau et al. (1982a In order to correlate the lack of pathogenicity after i.m. inoculation with the ts phenotype, three independent revertants were isolated from clones of tsG 1 after three successive cycles of multiplication at 39.6 °C in BSR cells. Supernatants were titrated at 38-5 °C. For the three viruses plaquing efficiency was similar at 33 °C and 38 °C as was the multiplication at 33 °C and 39.6 °C (Fig. 1) confirming that they were temperature-resistant. They were called R 1-tsG 1, R2-tsG1 and and R3-tsG1. When inoculated intramuscularly into mice, the three revertants were found to be as pathogenic as the CVS strain (data not shown).
Localization and characterization of the ts mutation
Total protein synthesis was studied at the permissive temperature (PT) and NPT in BSR cells infected with tsG1 or CVS (Fig. 3) . As usual, viral infection did not markedly depress cellular protein synthesis. Because of the cellular background and the diffuse pattern of migration, the G protein could not be visualized but L, N, M1 and M2 were clearly visible. The quantity of viral proteins synthesized at the NPT in tsGl-infected ceils indicated that the mutant could be classified as F ÷ according to Saghi & Flamand (1979) . This suggested that the ts lesion was located in a protein that was not directly involved in the transcription and replication processes of the virus, i.e. the G or M2 proteins.
The G proteins of CVS and tsG 1 were then compared by the tryptic peptide mapping method (Lafay & B6n6jean, 1981 ; Dietzschold et al., 1983; Diallo, 1984) . Profiles of elution on a HPLC reverse phase column showed only one difference in a hydrophobic lysine peptide of the CVS and tsG1 glycoproteins (Fig. 4) , while arginine peptide mapping was similar (data not shown).
The nucleotide sequence of the G gene of tsG1 was determined by the dideoxy chain termination method, as described by Seif et al. (1985) , and compared to that of the CVS strain. The results are shown in Fig. 5 . A unique difference was found between tsG1 and CVS. It was 
. HPLC of tryptic peptides from the G proteins of tsG1 and CVS. [14C]Lysine-labelled CVS G protein (---) and [3H]lysine-labelled tsG1 G protein ( ).
There were three differences between our CVS glycoprotein sequence and that published by Yelverton et al. (1983) : at position 36 we found an isoleucine instead of a threonine, at position 122 a leucine as in the ERA strain instead of a valine, and at position 156 a glycine instead of a serine as in the PV strain (Anilionis et al., 1981 ; Tordo et al., 1986) .
In order to confirm that the mutation in position 132 was responsible for the ts phenotype, a partial sequence of the G gene of the three revertants was obtained (Fig. 5) . In every instance the CVS sequence was restored in position 132 (Phe --, Leu), thus confirming that the ts lesion is located at that position.
The ts mutation is situated between two regions of the glycoprotein which apparently constitute antigenic site II (Pr6haud et al., 1988) . We have demonstrated that a mutation in position 147 between those two regions can greatly modify site II. We therefore investigated the antigenic characteristics of tsG 1 to see whether they were similar to those of the CVS strain. The mutant was exposed to MAbs defining the two major sites of the viral glycoprotein and several minor sites Seifet al., 1985 : Pr6haud et al., 1988 . tsG 1 and CVS were similar in their sensitivity to neutralizing MAbs (data not shown). The ts mutation did not modify the antigenicity of the glycoprotein.
Lack of complementation of ts mutants affected in different viral proteins
The availability of ts mutations known to affect different genes (G gene for tsG1, M1 gene for tsO52 and tsO106) allowed us to reinvestigate the possibility of complementation between rabies virus ts mutants. Mixed infections were performed with tsG 1 and these two ts mutants, as well as mutants with the F-and F ÷ phenotypes. In no instance could complementation be detected (data not shown).
Effect of the ts mutation on the transport of the G protein
Several ts mutations in viral glycoproteins have been described so far. All of them block its transport to the external membrane either in the rough endoplasmic reticulum (RER) or in the Golgi apparatus (Gallione & Rose, 1985; Arias et al., 1983; Nakajima et al., 1986; Schuy et al., 1986) . We investigated the fate of tsG1 glycoprotein in cell membranes. Non-infected and BSR cells infected for 24 h, incubated at the NPT, were permeabilized and treated with anti-viral nucleocapsid fluorescent antibodies. As expected infected cells were brightly fluorescent (Fig. 6b) , thus confirming that viral protein synthesis induced by C ¥ S , tsG 1 or R-tsG 1 was comparable at the N PT. In the absence of permeabilization no fluorescence could be detected (Fig. 6g) , an observation which indicates that the integrity of the plasma membrane was preserved under our experimental conditions.
An avirulent ts rabies virus mutant (a)
When cells were treated with pre-warmed anti-G MAb, washed and fixed, then treated with fluorescent anti-mouse immunoglobulins, external membranes were heavily labelled, although no fluorescence could be detected in mock-infected cells (Fig. 6c) . No difference in the amount of fluorescence was detectable between tsG 1-, CVS-or R-tsGl-infected cells. Thus the tsG1 G protein seems to be efficiently transported to the plasma membrane at the NPT.
Lack of e.p.e, of tsG1 in cell cultures
Rabies virus is poorly cytopathic, and CVS-infected cells incubated at 33 °C survived for several days. At 37 or 39.6 °C, however, survival was reduced to 2 or 3 days. After this period very few cells remained alive; survivors eventually generate a persistent infection (Tuffereau & Flamand, 1983) .
The survival of cells inoculated with tsG1 or R-tsG1 on day 0 with m.o.i, of 100 p.f.u./cell has been compared (data not shown). In parallel cultures it has been verified that all were indeed infected and contained similar amounts of viral material after 24 h. After 3 days at 33 °C, as expected, tsG 1-and Rl-tsG 1-infected cells were still alive and appeared very similar, although different from the control. After 3 days at 39.6 °C, Rl-tsGl-infected cells were dying, while no c.p.e, was seen in tsG 1-infected cells. Moreover, the latter cells could allow the establishment of a persistent infection which could be maintained at 37 °C, a temperature at which maturation of the mutant is normal.
DISCUSSION
We have recently isolated a new spontaneous ts and attenuated mutant of the CVS strain of rabies virus, tsG1. The mutation affects position 132 of the viral G protein, where a leucine is replaced by a phenylalanine, tsG 1 belongs to the F + group of rabies virus ts mutants, as defined by Saghi & Flamand (1979) . At the NPT viral proteins accumulated in tsGl-infected cells, indicating that a significant level of replication and secondary transcription could occur. Therefore, as demonstrated for other rhabdoviruses (see recent review by Rose & Schubert, 1987) , the rabies G protein is not directly involved in these processes.
No complementation was observed between tsG1 and other rabies virus ts mutants, even those which were certainly affected in a different protein such as tsO52 and tsO106, an observation which confirms previous results (Bussereau et al., 1982 b) . Why rabies virus mutants failed to complement each other, unlike other rhabdovirus ts mutants (see recent review by Pringle, 1987) , remains an intriguing issue. It can be postulated that viral synthesis is localized in cell compartments or linked to fixed structures such as the cytoskeleton, and that viral material does not move around with cytoplasmic flow. It is somewhat paradoxical that a virus which does not complement or recombine, and which should therefore be unfavourable for genetic research, gave rise to such useful types of mutants.
tsG1 is the first ts mutant of CVS to exhibit complete avirulence for adult mice after i.m. inoculation, associated with a very high protective power. This phenotype could reflect the fact that at the temperature of the mice (around 38.5 °C) tsG1 establishes an equilibrium between enough residual growth to stimulate the immune system and sufficient inhibition of viral propagation to be innocuous for the animal. On the other hand, the apathogenic phenotype could indicate that tsG 1 is less cytopathic for neurons, as found in vitro for BSR cells. It would be very interesting to have a mutant that was invasive without impairing the activity of the neurons.
The lack of c.p.e, of tsG 1 is intriguing; it is not due to a lack of viral maturation, since it is also observed at 37 °C, a temperature which is permissive for the mutant. Whether or not it is a direct consequence of the amino acid substitution observed in position 132 (Leu to Phe) could be studied by isolating partial revertants having a second mutation in addition to phenylalanine in position 132, which would be temperature-resistant but still apathogenic by the i.m. route. Unfortunately, the three revertants isolated in cell cultures had returned to the initial amino acid at position 132. Another approach would be to isolate pathogenic revertants from brains of suckling mice dying from infection with tsG1. These revertants isolated by using a criterion other than temperature resistance could be informative.
We established that it is possible to select avirulent mutants of rabies virus on the basis of their resistance to neutralization with appropriate MAbs (248-8 and 194-2 from the Wistar collection, 50AD1 and others from our own collection) (Coulon et al., 1982 (Coulon et al., , 1983 unpublished results) .
Since tsG 1 is sensitive to every MAb that neutralizes CVS, it has been possible to isolate tsG1 variants resisting neutralization to 248-8 or 50AD1. Some of these mutants have lost virulence for adult animals by the i.e. route of inoculation, which was not the case for tsG1. They are indeed double mutants, having both known mutations leading to avirulence, Leu to Phe in position 132 and Arg to Gin in position 333. As expected, the combination of both mutations reduced the frequency of reversion to a pathogenic phenotype to an undetectable level, a characteristic which allows use of the double mutants as a live vaccine (Tidke et al., 1987) .
Vesicular stomatitis virus ts mutants affected in the viral G protein have been widely used to investigate the various steps of transmembrane protein transport. The mutants available at present are blocked either in the RER or Golgi apparatus (Zilberstein et al., 1980; Bergmann et al., 1981; Arnheiter et al., 1984; Gallione & Rose, 1985) . By contrast tsG1 seems to reach external membranes at the NPT as efficiently as CVS or Rl-tsG1, as revealed by the fixation of anti-G antibodies on infected cells carefully maintained at 39.6 °C. tsG1 would therefore be unique in this respect. What is the nature of the block in viral maturation 9. Since amino acid 132 is situated in the ectodomain of the protein, the mutation could prevent the association of G into trimers which constitute the viral spikes. It is also possible that this amino acid substitution modifies the conformation of the cytoplasmic domain by a long-distance effect, and therefore prevents its association with M2 or with the nucleocapsid. Alternatively, it can be postulated that an interaction with a cellular membrane protein that is essential for viral maturation cannot occur. Since very little is known concerning this last step of the viral cycle, tsG1 certainly deserves further investigation.
